Ataxion Secures $17,000,000 Series A Funding Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=5d066d1e-fd9c-4895-a281-8291f30c6e77 - Date
3/19/2014 - Company Name
Ataxion - Mailing Address
25 First Street Cambridge, MA 02141 USA - Company Description
Ataxion is a discovery-stage biopharmaceutical company developing novel therapies for rare, debilitating, and underserved neurologic diseases. - Website
Undisclosed
- Transaction Type
Venture Equity - Transaction Amount
$17,000,000 - Transaction Round
Series A - Proceeds Purposes
In addition to participating in the Series A investment, Biogen Idec is providing non-dilutive R&D and other funding to Ataxion. Biogen Idec will have the option to acquire Ataxion to continue development of the program upon completion of the Phase 1 multiple ascending dose (MAD) study at pre-negotiated terms, including upfront and milestone payments. - M&A Terms
- Venture Investor
Atlas Venture - Venture Investor
Biogen Idec
